NASDAQ: ALXO - ALX Oncology Holdings Inc.

Yield per half year: -72.2%
Dividend yield: 0.00%
Sector: Healthcare

Share chart ALX Oncology Holdings Inc.

Extended chart Simple chart
Financial Markets by TradingView

About ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc., иммуноонкологическая компания на клинической стадии, специализируется на разработке методов лечения пациентов, борющихся с раком. Его ведущим продуктом-кандидатом является ALX148, блокирующий CD47 терапевтический препарат, используемый для лечения миелодиспластических синдромов и острого миелоидного лейкоза, а также ряда показаний к солидным опухолям, включая плоскоклеточную опухоль головы и шеи и человеческий эпидермальный рецептор фактора роста 2, положительный для карциномы желудочно-пищеводного перехода.

more details
Компания была основана в 2015 году и базируется в Берлингейме, штат Калифорния.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2020-07-17
ISIN US00166B1052
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Див.доход ао 0
Сайт http://www.alxoncology.com
Цена ао 1.77
Change price per day: -7.06% (1.63)
Change price per week: -12.93% (1.74)
Change price per month: -17.21% (1.83)
Change price per 3 month: +3.06% (1.47)
Change price per half year: -72.2% (5.45)
Change price per year: -89.72% (14.74)
Change price per 3 year: -90.18% (15.43)
Change price per 5 year: 0% (1.515)
Change price per 10 year: 0% (1.515)
Change price per year to date: -6.48% (1.62)
All parameters

Underestimation

Title Value Grade
P/S 4.4 4
P/BV 3.42 5
P/E 0 0
EV/EBITDA -3.8 0
Total: 3.75

Efficiency

Title Value Grade
ROA, % -66.3 0
ROE, % -84.76 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.0662 10
Total: 9

Growth impulse

Title Value Grade
Yield Revenue, % -42.86 0
Yield Ebitda, % 742.57 10
Yield EPS, % 326.73 10
Total: 8
More

Transaction date Date of disclosure Insider Type Price Volume Quantity Share before, % Share after, % Document
11.07.2024 15.07.2024 Pons Jaume
PRESIDENT & CSO		 Sale 7.9 158 000 20000 0 -0.05 link
11.07.2024 15.07.2024 Pons Jaume
PRESIDENT & CSO		 Purchase 0.99 19 800 20000 0 0.05 link
05.07.2024 09.07.2024 Pinto Shelly
SVP, FINANCE AND CAO		 Sale 5.5 10 027 1823 0 0 link
04.06.2024 06.06.2024 Pons Jaume
PRESIDENT & CSO		 Sale 8.43 168 600 20000 0 -0.05 link
04.06.2024 06.06.2024 Pons Jaume
PRESIDENT & CSO		 Purchase 0.99 19 800 20000 0 0.05 link
14.03.2024 18.03.2024 Lettmann Jason
CHIEF EXECUTIVE OFFICER		 Purchase 11.31 49 764 4400 0 0.01 link

Institutions Volume Share, %
venBio Partners LLC 9699925 19.34
FMR, LLC 7472821 14.9
Vivo Capital, LLC 4220048 8.41
Redmile Group, LLC 3659264 7.3
Cormorant Asset Management, LP 3142079 6.27
Orbimed Advisors LLC. 3095000 6.17
Blackrock Inc. 2235093 4.46
Vestal Point Capital, LP 1655000 3.3
Vanguard Group Inc 1502409 3
MPM BioImpact Capital LLC 1264759 2.52

ETF Share, % Profitability for 1 year, % Dividends, %
Virtus LifeSci Biotech Clinical Trials ETF 0.19423 63.04 0.33
Vanguard U.S. Momentum Factor ETF 0.07 30.05 1.05834
Inspire Small/Mid Cap ETF 0.06571 28.65 1.92038
iShares Micro-Cap ETF 0.01828 17.09 1.54048
Principal Healthcare Innovators ETF 0.01087 618.5 0.8416
Invesco Nasdaq Biotechnology ETF 0.01087 28.58 0.8565
Future Tech ETF 0.01087 426.34 0.8416
Vanguard Russell 2000 Growth ETF 0.01 23.05 0.60264
ProShares Ultra Nasdaq Biotechnology 0.00742 51.7 0.85651
iShares Russell 2000 Growth ETF 0.00513 38.04 0.6026
Schwab U.S. Small-Cap ETF 0.00159 17.47 1.51433
ProShares UltraPro Russell2000 0.00148 89.82 1.47873
iShares Morningstar Small Cap Value ETF 0.00129 26.7 2.50476
iShares Morningstar Small-Cap Value ETF 0.00129 201.65 2.50476
iShares Morningstar Small-Cap ETF 0.00097 30.1 1.60498
iShares Morningstar Small-Cap ETF 0.00097 391.25 1.60498
iShares Morningstar Small-Cap Growth ETF 0.00082 33.63 0.72598
iShares Morningstar Small-Cap Growth ETF 0.00082 587.89 0.72598
ProShares Hedge Replication ETF 0.00043 5.92 1.47892
Schwab U.S. Broad Market ETF 0.00014 24.86 1.43354
iShares Russell 3000 ETF 0.00013 24.83 1.43482
Avantis U.S. Equity ETF 0.00004 23.04 1.59151
Dimensional US Core Equity Market ETF 0.00002 30.98 1.40618
Vanguard Russell 2000 ETF 0 17.16 1.48801
Vanguard Russell 3000 ETF 0 31.87 1.43817



Head Job title Payment Year of birth
Dr. Jaume Pons Ph.D. Founder, President, Chief Scientific Officer & Director 856.29k 1966 (59 years)
Dr. Sophia Randolph M.D., Ph.D. Chief Medical Officer & Director 637.24k 1968 (57 years)
Dr. Michael Chang Ph.D. Vice President of Operations N/A
Ms. Shelly Pinto Senior VP of Finance & Chief Accounting Officer 508.26k 1977 (48 years)
Mr. Peter S. Garcia M.B.A. Chief Financial Officer 631.11k 1962 (63 years)
Dr. Athanasios Tsiatis M.D. Senior Vice President of Clinical Development N/A
Dr. Christopher Byrd J.D., Ph.D. General Counsel N/A
Mr. Jason W. Lettmann CEO & Director 60.5k 1977 (48 years)
Dr. Lin Yeong-Liang M.D., M.S. Senior Vice President of Drug Safety & Pharmacovigilance N/A
Caitlyn Doherty Manager of Investor Relations & Corporate Communications

Address: United States, Burlingame, CA , 866 Malcolm Road - open in Google maps, open in Yandex maps
Website: http://www.alxoncology.com